Click here to find out your risk of stroke.
This interactive tool measures the chance of having a stroke in the next 5 years, for people who are age 55 or older and have atrial fibrillation. To calculate your score, the tool uses the information you enter.
This tool is based on information from the Framingham Heart Study. Since 1948 the Framingham Heart Study has studied the progression of heart disease and its risk factors. The data from this study has been used to make a risk assessment.
You should be aware, though, that the tool cannot be applied to everyone. This tool does not work for people who:
The values you enter include the most important risk factors for stroke. They are:
Health Tools help you make wise health decisions or take action to improve your health.
|Interactive tools are designed to help people determine health risks, ideal weight, target heart rate, and more.|
|Stroke Risk From Atrial Fibrillation|
Your score will appear in as a value from 1% to 99%. If your score is 5%, it means that 5 out of 100 people with this level of risk will have a stroke in the next 5 years. If your score is 10%, it means that 10 out of 100 people with this level of risk will have a stroke in the next 5 years.
These percentages are one way your doctor can decide if an anticoagulant (blood thinner), such as warfarin, is the right medicine to help lower your risk of stroke. Talk with your doctor about the best way to lower your risk of stroke.
If you are above a 10% risk, talk to your doctor about taking an anticoagulant. You will want to weigh the benefits of reducing your risk of stroke against the risks of taking an anticoagulant. These medicines work well to prevent stroke. But they also increase the risk of bleeding.
If you are at a 10% risk or lower, you may get enough protection from stroke by taking ASA. ASA may be a good choice if you are young and have no other heart or health problems or if you can't take an anticoagulant safely. ASA doesn't work as well as an anticoagulant to reduce your stroke risk. But ASA is less likely to cause bleeding problems.
Other antiplatelet medicines, such as clopidogrel (Plavix), may be used. Your doctor may have you take them with ASA or instead of ASA. When ASA and clopidogrel are used together, they may reduce the risk for stroke more than ASA alone. But this combination is also more likely to cause bleeding than ASA alone.
Talk to your doctor about how to lower your risk of stroke if you have atrial fibrillation. Medicine and lifestyle changes, such as quitting smoking or eating a heart-healthy diet, can help lower your risk of stroke.
For help deciding if warfarin, or another medicine, is right for you, see Atrial Fibrillation: Should I Take Warfarin to Prevent Stroke?
For more information, see the topic Atrial Fibrillation.
This tool was derived from Wang TJ, et al. (2003). A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: The Framingham heart study. JAMA, 290(8): 1049–1056. The Framingham Heart Study is a project of the National Heart, Lung, and Blood Institute, a part of the National Institutes of Health and the U.S. Department of Health and Human Services, and Boston University. More information is available online at www.framinghamheartstudy.org.
Other Works Consulted
- Fuster V, et al. (2006). ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation—Executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing committee to revise the 2001 guidelines for the management of patients with atrial fibrillation). Circulation, 114(7): 700–752. [Erratum in Circulation, 116(6): e137.]
- Wang TJ, et al. (2003). A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: The Framingham heart study. JAMA, 290(8): 1049–1056.
- Wann LS, et al. (2011). 2011 ACCF/AHA/HRS focused updated on the management of patients with atrial fibrillation (update on dabigatran): A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. Published online February 14, 2011 (doi:10.1161/CIR.0b013e31820fl4c0).
|Primary Medical Reviewer||E. Gregory Thompson, MD - Internal Medicine|
|Primary Medical Reviewer||Brian D. O'Brien, MD - Internal Medicine|
|Specialist Medical Reviewer||John M. Miller, MD - Electrophysiology|
|Last Revised||August 24, 2011|
This information does not replace the advice of a doctor. Healthwise, Incorporated disclaims any warranty or liability for your use of this information.